Dosing Strategies for Improving the Risk-Benefit Profile of Ponatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase

The treatment of chronic myeloid leukemia (CML) has been advanced by the development of small-molecule tyrosine kinase inhibitors (TKIs), which target the fusion protein BCR-ABL1 expressed by the Philadelphia chromosome. Ponatinib is a 3rd generation TKI that binds BCR-ABL1 with high affinity and in...

Descripción completa

Detalles Bibliográficos
Autores principales: Castagnetti, Fausto, Pane, Fabrizio, Rosti, Gianantonio, Saglio, Giuseppe, Breccia, Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8009177/
https://www.ncbi.nlm.nih.gov/pubmed/33796468
http://dx.doi.org/10.3389/fonc.2021.642005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8009177/
https://www.ncbi.nlm.nih.gov/pubmed/33796468
http://dx.doi.org/10.3389/fonc.2021.642005

Ejemplares similares